|
|
炎症水平相关指标与胃癌患者预后的关系
|
Abstract:
胃癌(Gastric cancer)被定义为源自胃的原发性上皮恶性肿瘤，是一种具有多种危险因素的复杂异质性疾病。尽管在过去几十年中，GC在各个国家的发病率和死亡率总体呈下降趋势，但GC仍然是全球第五大最常见的恶性肿瘤和癌症相关死亡的第四大原因。早期胃癌的主要治疗方法是内镜切除术，非早期胃癌通过手术治疗。围手术期或辅助化疗可提高1B期或更高分期癌症患者的生存率，晚期胃癌采用序贯化疗，从一线铂类和氟嘧啶双联疗法开始。获准用于治疗胃癌的靶向疗法包括曲妥珠单抗(HER2阳性患者一线治疗)、雷莫芦单抗(抗血管生成二线治疗)和纳武利尤单抗或帕博利珠单抗(抗PD-1三线治疗)。在过去的40年中，基于氟尿嘧啶的方案仍然是辅助化疗的一线选择。然而，几项经典临床试验表明，辅助化疗组患者的总生存期仅略高于单手术组，这表明并非所有患者都能从辅助化疗中获益。这些发现强烈强调了对GC进行进一步分类、识别具有不同复发风险的患者以及确定化疗获益可能性的迫切需要。因此，如何延长胃癌患者的生存时间、提高患者的生存率是目前临床研究的重点。营养状况较差常存在于恶性肿瘤患者中，不良的营养状况可能会增加患者围术期并发症的发生率及死亡率，导致较差的预后；炎症与肿瘤常常相互作用，肿瘤诱发机体炎症加剧、炎症进一步促进肿瘤进程。目前临床上已有多种反应机体营养状况及炎症水平的指标，本文就患者的营养状况、炎症水平相关指标与胃癌患者预后的关系进行综述，为临床医生提供预测患者预后的信息，为患者制定个性化且具体的诊疗方案。
Gastric cancer, defined as a primary epithelial malignant tumor derived from the stomach, is a complex and heterogeneous disease with multiple risk factors. Despite the overall decreasing trend of GC incidence and mortality in various countries over the past decades, GC remains the fifth most common cause of malignancy and fourth cancer-related death worldwide. The main treatment for early gastric cancer is endoscopic resection. Non-early surgical gastric cancer is treated by surgery. Perioperative or adjuvant chemotherapy improves survival in patients with stage 1B or higher cancer. Advanced gastric cancer uses sequential chemotherapy, starting with first-line platinum and fluoropyrimidine bitherapy. Targeted therapies approved for the treatment of gastric cancer include trastuzumab (first-line therapy in HER2-positive patients), ramolumab (second-line therapy), and navulizumab or pabolizumab (anti-PD-1 third-line therapy). In the past 40 years, fluorouracil-based regimens remain the first-line option for adjuvant chemotherapy. However, several classic clinical trials showed that overall survival in patients in the adjuvant chemotherapy group was only slightly higher than in the single-surgery group, suggesting that not all patients benefit from adjuvant chemotherapy. These findings strongly highlight the urgent need for further classification of GC, identification of patients with different risks of recurrence, and determining the possibility of benefit from chemotherapy. Therefore, how to prolong the survival time and improve the survival rate of GC patients is the focus of clinical research. Poor nutritional status often exists in patients with malignant tumors. Poor nutritional status may increase the incidence and mortality of perioperative complications and mortality of patients, leading to poor prognosis; inflammation and tumor often interact to induce inflammation and further promote the tumor process. At
| [1] | Yang, W.-J., Zhao, H.-P., Yu, Y., Wang, J.-H., Guo, L., Liu, J.-Y., Pu, J. and Lv, J. (2023) Updates on Global Epidemiology, Risk and Prognostic Factors of Gastric Cancer. World Journal of Gastroenterology, 29, 2452-2468. https://doi.org/10.3748/wjg.v29.i16.2452 |
| [2] | Wu, H., Wang, W., Tong, S. and Wu, C. (2015) Nucleostemin Regulates Proliferation and Migration of Gastric Cancer and Correlates with Its Malignancy. International Journal of Clinical and Experimental Medicine, 8, 17634-17643. |
| [3] | Mai, M., Takahashi, Y., Fujimoto, T. and Omote, K. (1994) [Neoadjuvant Chemotherapy for Far-Advanced Gastric Carcinoma]. Japanese Journal of Cancer and Chemotherapy, 21, 431-439. |
| [4] | Crookes, P., Leichman, C.G., Leichman, L., et al. (1997) Systemic Chemotherapy for Gastric Carcinoma Followed by Postoperative Intraperitoneal Therapy: A Final Report. Cancer, 79, 1767-1775. https://doi.org/10.1002/(SICI)1097-0142(19970501)79:9<1767::AID-CNCR19>3.0.CO;2-W |
| [5] | Gianni, L., Panzini, I., Tassinari, D., et al. (2001) Meta-Analyses of Randomized Trials of Adjuvant Chemotherapy in Gastric Cancer. Annals of Oncology, 12, 1179-1181. https://doi.org/10.1023/A:1011611821258 |
| [6] | Schuhmacher, C.P., Fink, U., Becker, K., et al. (2001) Neoadjuvant Therapy for Patients with Locally Advanced Gastric Carcinoma with Etoposide, Doxorubicin, and Cisplatinum. Closing Results after 5？Years of Follow-Up. Cancer, 91, 918-927. https://doi.org/10.1002/1097-0142(20010301)91:5<918::AID-CNCR1081>3.0.CO;2-W |
| [7] | Mirza, A., Pritchard, S. and Welch, I. (2013) The Postoperative Component of MAGIC Chemotherapy Is Associated with Improved Prognosis Following Surgical Resection in Gastric and Gastrooesophageal Junction Adenocarcinomas. International Journal of Surgical Oncology, 2013, Article ID: 781742. https://doi.org/10.1155/2013/781742 |
| [8] | Singh, N., Badrun, D. and Ghatage, P. (2020) State of the Art and Up-and-Coming Angiogenesis Inhibitors for Ovarian Cancer. Expert Opinion on Pharmacotherapy, 21, 1579-1590. https://doi.org/10.1080/14656566.2020.1775813 |
| [9] | Lv, Y., Song, L., Chang, L., et al. (2016) Bevacizumab Followed by Chemotherapy Is Potential Therapy for Gastric Cancer. Journal of Balkan Union of Oncology, 21, 1466-1470. |
| [10] | Shah, M.A., Ramanathan, R.K., Ilson, D.H., et al. (2006) Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients with Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology, 24, 5201-5206. https://doi.org/10.1200/JCO.2006.08.0887 |
| [11] | Li, Y., Wang, C., Xu, M., et al. (2017) Preoperative NLR for Predicting Survival Rate after Radical Resection Combined with Adjuvant Immunotherapy with CIK and Postoperative Chemotherapy in Gastric Cancer. Journal of Cancer Research and Clinical Oncology, 143, 861-871. https://doi.org/10.1007/s00432-016-2330-1 |
| [12] | Cai, X.-Y., Wang, X.-F., Li, J., et al. (2016) High Expression of CD39 in Gastric Cancer Reduces Patient Outcome Following Radical Resection. Oncology Letters, 12, 4080-4086. https://doi.org/10.3892/ol.2016.5189 |
| [13] | Andreyev, H.J., Norman, A.R., Oates, J., et al. (1998) Why Do Patients with Weight Loss Have a Worse Outcome When Undergoing Chemotherapy for Gastrointestinal Malignancies? European Journal of Cancer, 34, 503-509. https://doi.org/10.1016/S0959-8049(97)10090-9 |
| [14] | Thoresen, L., Fjeldstad, I., Krogstad, K., et al. (2002) Nutritional Status of Patients with Advanced Cancer: The Value of Using the Subjective Global Assessment of Nutritional Status as a Screening Tool. Palliative Medicine, 16, 33-42. https://doi.org/10.1191/0269216302pm486oa |
| [15] | Rosania, R., Chiapponi, C., Malfertheiner, P., et al. (2016) Nutrition in Patients with Gastric Cancer: An Update. Gastrointestinal Tumors, 2, 178-187. https://doi.org/10.1159/000445188 |
| [16] | Vergara, N., Montoya, J.E., Luna, H.G., et al. (2013) Quality of Life and Nutritional Status among Cancer Patients on Chemotherapy. Oman Medical Journal, 28, 270-274. https://doi.org/10.5001/omj.2013.75 |
| [17] | Marin Caro, M.M., Laviano, A. and Pichard, C. (2007) Nutritional Intervention and Quality of Life in Adult Oncology Patients. Clinical Nutrition, 26, 289-301. https://doi.org/10.1016/j.clnu.2007.01.005 |
| [18] | Lim, S., Brown, J.L., Washington, T.A., et al. (2020) Development and Progression of Cancer Cachexia: Perspectives from Bench to Bedside. Sports Medicine and Health Science, 2, 177-185. https://doi.org/10.1016/j.smhs.2020.10.003 |
| [19] | Esper, D.H. and Harb, W.A. (2005) The Cancer Cachexia Syndrome: A Review of Metabolic and Clinical Manifestations. Nutrition in Clinical Practice, 20, 369-376. https://doi.org/10.1177/0115426505020004369 |
| [20] | Heys, S.D., Walker, L.G., Deehan, D.J. and Eremin, O.E. (1998) Serum Albumin: A Prognostic Indicator in Patients with Colorectal Cancer. Journal of the Royal College of Surgeons of Edinburgh, 43, 163-168. |
| [21] | Han, K.S. and Hong, S.J. (2014) Serum Alkaline Phosphatase Differentiates Prostate-Specific Antigen Flare from Early Disease Progression after Docetaxel Chemotherapy in Castration-Resistant Prostate Cancer with Bone Metastasis. Journal of Cancer Research and Clinical Oncology, 140, 1769-1776. https://doi.org/10.1007/s00432-014-1710-7 |
| [22] | Kim, J.M., Kwon, C.H.D., Joh, J.-W., Park, J.B., Ko, J.S., Lee, J.H., Kim, S.J. and Park, C.-K. (2013) The Effect of Alkaline Phosphatase and Intrahepatic Metastases in Large Hepatocellular Carcinoma. World Journal of Surgical Oncology, 11, Article No. 40. https://doi.org/10.1186/1477-7819-11-40 |
| [23] | Zhang, L. and Gong, Z. (2017) Clinical Characteristics and Prognostic Factors in Bone Metastases from Lung Cancer. Medical Science Monitor, 23, 4087-4094. https://doi.org/10.12659/MSM.902971 |
| [24] | Haarhaus, M., Brandenburg, V., Kalantar-Zadeh, K., et al. (2017) Alkaline Hosphatase: A Novel Treatment Target for Cardiovascular Disease in CKD. Nature Reviews Nephrology, 13, 429-442. https://doi.org/10.1038/nrneph.2017.60 |
| [25] | Long, Z.Q., Hua, X., Zhang, W.W., et al. (2019) Prognostic Impact of the Pretreatment Albumin to Alkaline Phosphatase Ratio for Nonmetastatic Breast Cancer Patients. Cancer Management and Research, 11, 4809-4814. https://doi.org/10.2147/CMAR.S200759 |
| [26] | Chen, B., Dai, D., Tang, H., Chen, X., Ai, X., Huang, X., Wei, W. and Xie, X. (2016) Pre-Treatment Serum Alkaline Phosphatase and Lactate Dehydrogenase as Prognostic Factors in Triple Negative Breast Cancer. Journal of Cancer, 7, 2309-2316. https://doi.org/10.7150/jca.16622 |
| [27] | Namikawa, T., Ishida, N., Tsuda, S., Fujisawa, K., Munekage, E., Iwabu, J., Munekage, M., Uemura, S., Tsujii, S., Tamura, T., Yatabe, T., Maeda, H., Kitagawa, H., Kobayashi, M. and Hanazaki, K. (2019) Prognostic Significance of Serum Alkaline Phosphatase and Lactate Dehydrogenase Levels in Patients with Unresectable Advanced Gastric Cancer. Gastric Cancer, 22, 684-691. https://doi.org/10.1007/s10120-018-0897-8 |
| [28] | Rodriguez-Vita, J. and Lawrence, T. (2010) The Resolution of Inflammation and Cancer. Cytokine & Growth Factor Reviews, 21, 61-65. https://doi.org/10.1016/j.cytogfr.2009.11.006 |
| [29] | Miller-Ocuin, J.L., Liang, X., Boone, B.A., et al. (2019) DNA Released from Neutrophil Extracellular Traps (NETs) Activates Pancreatic Stellate Cells and Enhances Pancreatic Tumor Growth. OncoImmunology, 8, e1605822. https://doi.org/10.1080/2162402X.2019.1605822 |
| [30] | 商安全, 李冬. 中性粒细胞与肿瘤: 是敌是友? [J]. 国际检验医学杂志, 2020, 41(1): 104-110. |
| [31] | Cools-Lartigue, J., Spicer, J., McDonald, B., et al. (2013) Neutrophil Extracellular Traps Sequester Circulating Tumor Cells and Promote Metastasis. The Journal of Clinical Investigation, 123, 3446-3458. |
| [32] | Pillay, J., Den Braber, I., Vrisekoop, N., et al. (2010) In vivo Labeling with 2H2O Reveals a Human Neutrophil Lifespan of 5.4 Days. Blood, 116, 625-627. https://doi.org/10.1182/blood-2010-01-259028 |
| [33] | Liang, W. and Ferrara, N. (2016) The Complex Role of Neutrophils in Tumor Angiogenesis and Metastasis. Cancer Immunology Research, 4, 83-91. https://doi.org/10.1158/2326-6066.CIR-15-0313 |
| [34] | Swierczak, A., Mouchemore, K.A., Hamilton, J.A. and Anderson, R.L. (2015) Neutrophils: Important Contributors to Tumor Progression and Metastasis. Cancer Metastasis Reviews, 34, 735-751. https://doi.org/10.1007/s10555-015-9594-9 |
| [35] | Ogiya, R., Niikura, N., Kumaki, N., et al. (2016) Comparison of Tumor-Infiltrating Lymphocytes between Primary and Metastatic Tumors in Breast Cancer Patients. Cancer Science, 107, 1730-1735. https://doi.org/10.1111/cas.13101 |
| [36] | Fang, T., Wang, Y., Yin, X., Zhai, Z., Zhang, Y., Yang, Y., You, Q., Li, Z., Ma, Y., Li, C., Song, H., Shi, H., Zhang, Y., Yu, X., Gao, H., Sun, Y., Xie, R. and Xue, Y. (2020) Diagnostic Sensitivity of NLR and PLR in Early Diagnosis of Gastric Cancer. Journal of Immunology Research, 2020, Article ID: 9146042. https://doi.org/10.1155/2020/9146042 |
| [37] | Gay, L.J. and Felding-Habermann, B. (2011) Contribution of Platelets to Tumour Metastasis. Nature Reviews Cancer, 11, 123-134. https://doi.org/10.1038/nrc3004 |
| [38] | Banks, R.E., Forbes, M.A., Kinsey, S.E., et al. (1998) Release of the Angiogenic Cytokine Vascular Endothelial Growth Factor (VEGF) from Platelets: Significance for VEGF Measurements and Cancer Biology. British Journal of Cancer, 77, 956-964. https://doi.org/10.1038/bjc.1998.158 |
| [39] | Zhou, X., Du, Y., Huang, Z., Xu, J., Qiu, T., Wang, J., Wang, T., Zhu, W. and Liu, P. (2014) Prognostic Value of PLR in Various Cancers: A Meta-Analysis. PLOS ONE, 9, e101119. https://doi.org/10.1371/journal.pone.0101119 |
| [40] | Cruz-Ramos, M., Del Puerto-Nevado, L., Zheng, B., Lopez-Bajo, R., Cebrian, A., Rodriguez-Remirez, M., Garcia-Garcia, L., Solanes-Casado, S. and Garcia-Foncillas, J. (2019) Prognostic Significance of Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Older Patients with Metastatic Colorectal Cancer. Journal of Geriatric Oncology, 10, 742-748. https://doi.org/10.1016/j.jgo.2018.10.002 |
| [41] | Zhou, X., Xu, L., Huang, Z., Zhang, L., Zhang, H., Zhu, W. and Liu, P. (2016) The Hematologic Markers as Prognostic Factors in Patients with Resectable Gastric Cancer. Cancer Biomarkers, 17, 359-367. https://doi.org/10.3233/CBM-160648 |
| [42] | Essager, M., Neofytou, K., Chaudry, M.A. and Allum, W.H. (2015) Prognostic Impact of Preoperative Platelets to Lymphocytes Ratio (PLR) on Survival for Oesophageal and Junctional Carcinoma Treated with Neoadjuvant Chemotherapy: A Retrospective Monocentric Study on 153 Patients. European Journal of Surgical Oncology, 41, 1316-1323. https://doi.org/10.1016/j.ejso.2015.06.007 |
| [43] | Yoon, H.-J., Kim, B.S., Moon, C.M., Yoo, J., Lee, K.E. and Kim, Y. (2018) Prognostic Value of Diffuse Splenic FDG Uptake on PET/CT in Patients with Gastric Cancer. PLOS ONE, 13, e0196110. https://doi.org/10.1371/journal.pone.0196110 |
| [44] | Urabe, M., Yamashita, H., Watanabe, T. and Seto, Y. (2018) Comparison of Prognostic Abilities among Preoperative Laboratory Data Indices in Patients with Resectable Gastric and Esophagogastric Junction Adenocarcinoma. World Journal of Surgery, 42, 185-194. https://doi.org/10.1007/s00268-017-4146-9 |
| [45] | Lian, L., Xia, Y.-Y., Zhou, C., Shen, X.-M., Li, X.-L., Han, S.-G., Zheng, Y., Mao, Z.-Q., Gong, F.-R., Wu, M.-Y., et al. (2015) Application of Platelet/Lymphocyte and Neutrophil/Lymphocyte Ratios in Early Diagnosis and Prognostic Prediction in Patients with Resectable Gastric Cancer. Cancer Biomarkers, 15, 899-907. https://doi.org/10.3233/CBM-150534 |
| [46] | Hu, B., Yang, X.-R., Xu, Y., et al. (2014) Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma. Clinical Cancer Research, 20, 6212-6222. https://doi.org/10.1158/1078-0432.CCR-14-0442 |
| [47] | Wang, K., Diao, F., Ye, Z., et al. (2017) Prognostic Value of Systemic Immune-Inflammation Index in Patients with Gastric Cancer. Chinese Journal of Cancer, 36, Article No. 75. https://doi.org/10.1186/s40880-017-0243-2 |
| [48] | 张宇, 汪亦民, 薛英威. 全身免疫炎症指数(SII)与胃癌患者临床病理因素及预后的相关性[J]. 现代肿瘤医学, 2021, 29(3): 441-445. |
| [49] | Hirahara, N., Tajima, Y., Matsubara, T., et al. (2021) Systemic Immune-Inflammation Index Predicts Overall Survival in Patients with Gastric Cancer: A Propensity Score-Matched Analysis. Journal of Gastrointestinal Surgery, 25, 1124-1133. https://doi.org/10.1007/s11605-020-04710-7 |
| [50] | Wang, D., Hu, X., Xiao, L., et al. (2021) Prognostic Nutritional Index and Systemic Immune-Inflammation Index Predict the Prognosis of Patients with HCC. Journal of Gastrointestinal Surgery, 25, 421-427. https://doi.org/10.1007/s11605-019-04492-7 |
| [51] | Chen, J.-H., Zhai, E.-T., Yuan, Y.-J., et al. (2017) Systemic Immune-Inflammation Index for Predicting Prognosis of Colorectal Cancer. World Journal of Gastroenterology, 23, 6261-6272. https://doi.org/10.3748/wjg.v23.i34.6261 |
